(β-Asp5)-delta-Sleep Inducing Peptide
Need Assistance?
  • US & Canada:
    +
  • UK: +

(β-Asp5)-delta-Sleep Inducing Peptide

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

(β-Asp5)-delta-Sleep Inducing Peptide, a DSIP analog, is a good substrate for the protein L-isoaspartyl methyltransferase, an enzyme occuring in the brain involved in repairing age-damaged proteins containing atypical iosaspartyl peptide bonds.

Category
Others
Catalog number
BAT-015078
CAS number
82602-88-8
Molecular Formula
C35H48N10O15
Molecular Weight
848.81
(β-Asp5)-delta-Sleep Inducing Peptide
IUPAC Name
(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(3S)-3-[[2-[[2-[[(2S)-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]acetyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]acetyl]amino]pentanedioic acid
Synonyms
(β-Asp5)-Delta-Sleep Inducing Peptide (rabbit); H-Trp-Ala-Gly-Gly-Asp(Ala-Ser-Gly-Glu-OH)-OH; L-Tryptophyl-L-alanylglycylglycyl-L-β-aspartyl-L-alanyl-L-serylglycyl-L-glutamic acid; (3S,9S,12S,16S,25S,28S)-28-amino-9-(hydroxymethyl)-29-(1H-indol-3-yl)-12,25-dimethyl-5,8,11,14,18,21,24,27-octaoxo-4,7,10,13,17,20,23,26-octaazanonacosane-1,3,16-tricarboxylic acid; 5-Isoasp-delta sleep-inducing peptide
Appearance
White or Off-white Lyophilized Powder
Purity
≥95%
Density
1.5±0.1 g/cm3
Boiling Point
1526.5±65.0°C at 760 mmHg
Sequence
H2N-WAGG-βAsp-ASGE-OH
Storage
Store at -20°C
InChI
InChI=1S/C35H48N10O15/c1-16(42-32(55)20(36)9-18-11-37-21-6-4-3-5-19(18)21)30(53)39-12-26(48)38-13-27(49)44-23(35(59)60)10-25(47)41-17(2)31(54)45-24(15-46)33(56)40-14-28(50)43-22(34(57)58)7-8-29(51)52/h3-6,11,16-17,20,22-24,37,46H,7-10,12-15,36H2,1-2H3,(H,38,48)(H,39,53)(H,40,56)(H,41,47)(H,42,55)(H,43,50)(H,44,49)(H,45,54)(H,51,52)(H,57,58)(H,59,60)/t16-,17-,20-,22-,23-,24-/m0/s1
InChI Key
GGEQPJVCJLUAOE-GFVHOAGBSA-N
Canonical SMILES
CC(C(=O)NC(CO)C(=O)NCC(=O)NC(CCC(=O)O)C(=O)O)NC(=O)CC(C(=O)O)NC(=O)CNC(=O)CNC(=O)C(C)NC(=O)C(CC1=CNC2=CC=CC=C21)N
1. Delta-sleep-inducing peptide (DSIP): an update
M V Graf, A J Kastin Peptides. 1986 Nov-Dec;7(6):1165-87. doi: 10.1016/0196-9781(86)90148-8.
The isolation and characterization of delta-sleep-inducing peptide (DSIP) achieved from 1963 to 1977 were reviewed in 1984. The first reports describing sleep as well as extra-sleep effects of DSIP also were included in that work. Only two years later, much additional literature concerning DSIP has accumulated. Besides further sleep-inducing and/or -supporting effects of DSIP in animals, considerable work has been carried out to evaluate the potential use of the peptide for therapeutic purposes such as treatment of insomnia, pain, and withdrawal. Immunohistochemical as well as radioimmunochemical studies provided further insights into the natural occurrence of the nonpeptide and the distribution of DSIP-like material in the body, suggesting possible relations of the peptide to certain diseases. Various physiological functions of DSIP and a possible mechanism of action involving the modulation of adrenergic transmission remain to be established.
2. Delta-sleep-inducing peptide (DSIP): a review
M V Graf, A J Kastin Neurosci Biobehav Rev. 1984 Spring;8(1):83-93. doi: 10.1016/0149-7634(84)90022-8.
Since the turn of the century, it has been postulated that humoral factors induce sleep. Many compounds were proposed as sleep-factors, but only two of the sleep-peptides have been purified to homogeneity and characterized, so far. One of them, DSIP, was shown to be a nonapeptide of MW 849 and to induce mainly delta-sleep in rabbits, rats, mice, and humans, whereas in cats, the effect on REM sleep was more pronounced. A U-shaped activity curve was determined for the dose as well as for the time of infusion. DSIP-like material was found by RIA and immunohistochemistry in brain and by RIA in peripheral organs of the rat as well as in plasma of several mammals. In addition to sleep, the peptide also has been observed to affect electrophysiological activity, neurotransmitter levels in the brain, circadian and locomotor patterns, hormonal levels, psychological performance, and the activity of neuropharmacological drugs including their withdrawal.
Online Inquiry
Verification code
Inquiry Basket